Tiziana Life Sciences Ltd

NasdaqCM:TLSA Stock Report

Market Cap: US$76.7m

Tiziana Life Sciences Balance Sheet Health

Financial Health criteria checks 5/6

Tiziana Life Sciences has a total shareholder equity of $1.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.0M and $9.1M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$1.13m
EquityUS$1.86m
Total liabilitiesUS$9.11m
Total assetsUS$10.96m

Recent financial health updates

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Sep 19
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Jun 03
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Jan 16
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Recent updates

Tiziana Life Sciences: Awaiting Data Of Foralumab For Secondary Progressive Multiple Sclerosis

Dec 24

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Sep 19
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Jun 03
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Jan 16
Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct 12

Tiziana chief medical officer further increases holdings in company

Sep 23

Tiziana Life Sciences executive chairman further raises stake in company

Sep 16

Tiziana executive chairman raises stake in company again, buys more shares

Aug 25

Tiziana Life Sciences discloses share purchase by executive chairman

Aug 17

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Aug 15
Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Jul 15

Financial Position Analysis

Short Term Liabilities: TLSA's short term assets ($7.8M) do not cover its short term liabilities ($9.1M).

Long Term Liabilities: TLSA's short term assets ($7.8M) exceed its long term liabilities ($37.0K).


Debt to Equity History and Analysis

Debt Level: TLSA is debt free.

Reducing Debt: TLSA currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLSA has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: TLSA is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 23:36
End of Day Share Price 2025/01/08 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tiziana Life Sciences Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Robin CampbellEquity Development Limited
Raghuram SelvarajuH.C. Wainwright & Co.